Back to top
more

Chemed (CHE)

(Delayed Data from NYSE)

$423.33 USD

423.33
207,247

+5.48 (1.31%)

Updated Aug 4, 2025 04:00 PM ET

After-Market: $424.08 +0.75 (0.18%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

5-Strong Sell of 5         5

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 25% (62 out of 246)

Industry: Medical - Outpatient and Home Healthcare

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Here's Why You Should Add Chemed (CHE) to Your Portfolio Now

by Zacks Equity Research

Investors are optimistic about Chemed (CHE) on strong third-quarter performance and raised Roto-Rooter and earnings guidance for 2021.

Zacks Equity Research

Here's Why You Should Retain Baxter (BAX) Stock For Now

by Zacks Equity Research

Investors continue to be optimistic about Baxter (BAX) due to its strong product portfolio.

Zacks Equity Research

HealthEquity (HQY) Q3 Earnings Beat, FY 2022 View Lowered

by Zacks Equity Research

HealthEquity (HQY) witnesses solid growth in HSAs besides recording robust Interchange revenues in the third quarter of fiscal 2022.

Zacks Equity Research

Here's Why You Should Retain Tandem Diabetes (TNDM) for Now

by Zacks Equity Research

Investors are optimistic about Tandem Diabetes (TNDM) on strong worldwide demand for Control-IQ technology and raised 2021 sales guidance.

Zacks Equity Research

CVS Health (CVS) New Alliance to Boost Digital Transformation

by Zacks Equity Research

CVS Health's (CVS) collaboration with Microsoft will accelerate digital transformation and empower employees to provide more customized and affordable care.

Zacks Equity Research

Here's Why You Should Retain Abiomed (ABMD) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Abiomed (ABMD) due to its Impella product line strength.

Zacks Equity Research

BD's (BDX) Buyout of Venclose to Improve Patient Outcome

by Zacks Equity Research

BD's (BDX) acquisition of Venclose is expected to deliver a patient-centric approach to care.

Zacks Equity Research

Here's Why You Should Retain CVS Health (CVS) Stock for Now

by Zacks Equity Research

Investors are optimistic about CVS Health (CVS) on strong third-quarter 2021 results and raised full-year outlook.

Zacks Equity Research

Thermo Fisher (TMO) Launches K-12 COVID-19 Test in Texas Schools

by Zacks Equity Research

Thermo Fisher's (TMO) ReadyCheckGo program will enable Texas schools to have the options for fast, reliable testing to identify and limit the spread of COVID-19 quickly.

Zacks Equity Research

Abbott (ABT) Nutrition Sales Strong Amid Spike in COVID Cases

by Zacks Equity Research

Abbott (ABT) is registering strong growth in its more consumer-facing businesses like nutrition, established pharmaceuticals and diabetes care.

Zacks Equity Research

The Zacks Analyst Blog Highlights: Abbott Laboratories, West Pharmaceuticals Services, Baxter International and Chemed Corp

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Abbott Laboratories, West Pharmaceuticals Services, Baxter International and Chemed Corp

Zacks Equity Research

Quest Diagnostics (DGX) Expands Testing Suite With NGS Test

by Zacks Equity Research

Quest Diagnostics (DGX) offers Targeted Lung Panel Test at 2,200 conveniently located patient service centers across the United States.

Riya Anand headshot

4 MedTech Dividend Stocks in Focus on Amid Omicron Variant Panic

by Riya Anand

Abbott Laboratories (ABT), West Pharmaceuticals Services (WST), Baxter International (BAX) and Chemed Corporation (CHE) are high-yield dividend stocks with sustainable business models.

Zacks Equity Research

DaVita (DVA) Study Favors mRNA Vaccines for Dialysis Patients

by Zacks Equity Research

DaVita's (DVA) latest study indicates favorable outcomes for ESKD patients regarding the COVID-19 vaccines.

Zacks Equity Research

Masimo's (MASI) Rad-G Clinical Study Trial Outcome Favorable

by Zacks Equity Research

Masimo's (MASI) latest study results demonstrate that Rad-G Pulse Oximeter can help detect pediatric pneumonia.

Zacks Equity Research

3 Reasons to Retain Integer Holdings (ITGR) Stock For Now

by Zacks Equity Research

Investors continue to be optimistic about Integer Holdings (ITGR) owing to its improving non-medical sales and its focus on growth strategies.

Zacks Equity Research

SeaSpine (SPNE) Enhances ACDF Procedure With Admiral ACP System

by Zacks Equity Research

SeaSpine's (SPNE) next-generation Admiral ACP System covers the largest segment in the estimated $1.30-billion cervical spine surgery market.

Zacks Equity Research

Here's Why You Should Add Hill-Rom (HRC) to Your Portfolio

by Zacks Equity Research

Investors are optimistic about Hill-Rom (HRC) on strong fiscal fourth-quarter results and progress in digital health.

Zacks Equity Research

Here's Why You Should Retain Abbott (ABT) Stock For Now

by Zacks Equity Research

Investors are optimistic about Abbott (ABT) owing to strong third-quarter results and bullish 2021 outlook.

Zacks Equity Research

Bio Rad (BIO) Grows Internationally on New Product Launches

by Zacks Equity Research

Strength in Bio Rad's (BIO) key product lines across major geographic regions buoys optimism.

Zacks Equity Research

Here's Why You Should Invest in Bio-Rad (BIO) Stock Now

by Zacks Equity Research

Investors are optimistic about Bio-Rad (BIO) on strength in its key product lines and raised 2021 guidance.

Zacks Equity Research

CVS Health (CVS) Installs Time-Delay Safes in Texas Pharmacies

by Zacks Equity Research

CVS Health's (CVS) time-delay safes reduce theft and diversion of opioid medications and boost the security of stores, creating a safe environment for patients and staff.

Zacks Equity Research

Alcon (ALC) Surgical Arm Grows Amid Global Trade Disruption

by Zacks Equity Research

Segment wise, within Alcon's (ALC) Surgical arm, the portfolio of advanced technology intraocular lenses is driving increased penetration rates of ATIOLs.

Zacks Equity Research

Illumina's (ILMN) New Alliance to Accelerate Genomics in China

by Zacks Equity Research

Illumina's (ILMN) Genomics Incubator will support companies poised to deliver breakthrough applications in genomics and multiomics.

Zacks Equity Research

Here's Why You Should Buy Thermo Fisher (TMO) Stock Now

by Zacks Equity Research

Investors are optimistic about Thermo Fisher (TMO) on strength in end markets and raised 2021 guidance.